+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nitric oxide synthase inhibitor - Pipeline Insight, 2022

  • ID: 5504279
  • Drug Pipelines
  • January 2022
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • EyePoint Pharmaceuticals
  • MediciNova
  • NeurAxon
  • Neurophyxia
  • Reata Pharmaceuticals
  • vasopharm BIOTECH
This “Nitric oxide synthase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Nitric oxide synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Nitric oxide synthase inhibitors Understanding

Nitric oxide synthase inhibitors: Overview


Nitric oxide synthases are enzymes that generate nitric oxide in tissues. There are three isoforms of NOS. eNOS (endothelial NOS) and nNOS (neuronal NOS) are constitutively expressed and regulated by transcription and post-transcription processes. iNOS (inducible NOS) is released de novo in response to inflammation. NOS inhibitors of varying degrees of potency and selectivity are available and utilized in research studies. Nitric oxide inhibition could be detrimental to patients with cardiovascular and renal diseases. Nitric oxide is cardio-protective during ischemic events by causing coronary vasodilation and improving oxygen delivery. Nitric oxide inhibition also suppresses statin-induced oxygen delivery to myocardium. Nitric oxide inhibition could contribute to endothelial dysfunction and inflammatory syndrome in patients with autoimmune disease, leading to an escalation of cardiovascular morbidity and mortality Inhibiting nitric oxide or its production can thus also be of therapeutic benefit.

Nitric oxide synthase inhibitors - Pipeline Insight, 2022 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nitric oxide synthase inhibitors pipeline landscape is provided which includes the disease overview and Nitric oxide synthase inhibitors treatment guidelines. The assessment part of the report embraces, in depth Nitric oxide synthase inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nitric oxide synthase inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Nitric oxide synthase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Nitric oxide synthase inhibitors.

Nitric oxide synthase inhibitors Emerging Drugs Chapters


This segment of the Nitric oxide synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nitric oxide synthase inhibitors Emerging Drugs

VAS203: Vasopharm BIOTECH

VAS203 is an analogue of the natural co-factor biopterin, which is involved in the generation of nitric oxide by the Nitric Oxide Synthase (NOS) family of enzymes. The mechanism of action of VAS203 is believed to confer selective down regulation of inducible NOS (iNOS) without significantly inhibiting the function of other NOS enzymes. Vasopharm's ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma.

Nitric oxide synthase inhibitors: Therapeutic Assessment


This segment of the report provides insights about the different Nitric oxide synthase inhibitors drugs segregated based on following parameters that define the scope of the report.

Major Players in Nitric oxide synthase inhibitors


There are approx. 5+ key companies which are developing the therapies for Nitric oxide synthase inhibitors. The companies which have their Nitric oxide synthase inhibitors drug candidates in the most advanced stage, i.e. phase III include Vasopharm BIOTECH.

Phases


This report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Nitric oxide synthase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Peptides
  • Polymer
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nitric oxide synthase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nitric oxide synthase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nitric oxide synthase inhibitors drugs.

Nitric oxide synthase inhibitors Report Insights

  • Nitric oxide synthase inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Nitric oxide synthase inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Nitric oxide synthase inhibitors drugs?
  • How many Nitric oxide synthase inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nitric oxide synthase inhibitors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nitric oxide synthase inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Nitric oxide synthase inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • EyePoint Pharmaceuticals
  • MediciNova
  • NeurAxon
  • Neurophyxia
  • Reata Pharmaceuticals
  • vasopharm BIOTECH

IntroductionExecutive Summary
Nitric oxide synthase inhibitors: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)
  • Comparative Analysis

VAS203: Vasopharm BIOTECH
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis
2-iminobiotin: Neurophyxia
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Nitric oxide synthase inhibitors Key CompaniesNitric oxide synthase inhibitors Key ProductsNitric oxide synthase inhibitors- Unmet NeedsNitric oxide synthase inhibitors- Market Drivers and BarriersNitric oxide synthase inhibitors- Future Perspectives and ConclusionNitric oxide synthase inhibitors Analyst ViewsNitric oxide synthase inhibitors Key CompaniesAppendix
List of Tables
Table 1 Total Products for Nitric oxide synthase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Nitric oxide synthase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • EyePoint Pharmaceuticals
  • Reata Pharmaceuticals
  • vasopharm BIOTECH
  • Yiviva
  • NeurAxon
  • Neurophyxia
  • SaNOtize Research and Development
  • MediciNova
Note: Product cover images may vary from those shown